PROGNOSIS IN ADVANCED NON-SMALL CELL LUNG CANCER - A RETROSPECTIVE STUDY EXAMINING ECOG PERFORMANCE STATUS SCORES OF PATIENTS

Nida Sajid Ali Bangash; Natasha Hashim; Nahlah Elkudssiah Ismail

doi:10.22159/ajpcr.2017.v10i9.17134

Authors

Nida Sajid Ali Bangash Department of Pharmacy, Clinical BioPharmaceutics Research Group, Universiti Teknologi MARA, Puncak Alam Campus, 42300 Bandar Puncak Alam, Selangor, Malaysia.
Natasha Hashim Department of Oncology and Radiotherapy, Hospital Kuala Lumpur, 50300 Kuala Lumpur, Malaysia.
Nahlah Elkudssiah Ismail Deanâ€™s office, Faculty of Pharmacy, MAHSA University, Jalan SP2, Bandar Saujana Putra, 42610 Jenjarom Kuala Langat, Selangor.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i9.17134

Keywords:

Performance status, Survival, Advanced non-small cell lung cancer

Abstract

Â

Â Objective: Increasing prevalence and poor survival of advanced incurable non-small cell lung cancer (NSCLC) make it a major health problem globally, especially in developing countries. This awakens need for identification of the strongest prognostic factor that helps in the selection of appropriate treatment and hence palliates symptoms and improves survival. Lung cancer treatment guidelines advise performance status (PS) as the most established prognostic factor in advanced NSCLC patients. This study investigated the prognostic significance of PS.

Methods: An observational study was done for 163 advanced NSCLC adult Malaysian patients in Radiotherapy and Oncology Clinic, Hospital Kuala Lumpur, Malaysia. Demographic and clinical data were recorded. Kaplan-Meier test was used to measure median overall survival (OS) and Cox proportional hazard model to calculate the hazard ratio for different categories of Eastern Cooperative Oncology Group (ECOG) PS.

Results: The mean age and body weight were 56.7Â±10.1 years old and 57.42Â±13.5 kg, respectively. Majority patients were male (68.7%), Stage IV NSCLC (65.0%), and ECOG PS score of 2 (41.1%). ECOG PS had a significant association with age and body weight. Median OS was least for ECOG PS score of 4 (253 days) and was statistically significant (p=0.003). ECOG PS was a significant independent prognostic factor for survival in advanced NSCLC patients (p<0.001).

Conclusion: PS is a strong prognostic factor in advanced NSCLC.

Downloads

Download data is not yet available.

References

Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80(6):827-41.

Azzoli CG, Temin S, Aliff T, Baker S, Brahmer J, Johnson DH, et al. 2011 focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 2001;29(28):3825-31.

Boukovinas I, Kosmidis P. Treatment of non-small cell lung cancer patients with performance status 2 (PS2). Lung Cancer 2009;63(1):10-5.

Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest oncology group experience. J Clin Oncol 1991;9(9):1618-26.

Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949. p. 199-205.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J ClinOncol1982;5(6):649-55.

Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: Do patients and their oncologists agree? Br J Cancer2003;89(6):1022-7.

Simmons CP, Koinis F, Fallon MT, Fearon KC, Bowden J, Solheim TS, et al. Prognosis in advanced lung cancer-a prospective study examining key clinic-pathological factors. Lung Cancer 2015;88(3):304-9.

Liam CK, Pang YK, Leow CH, Poosparajah S, Menon A. Changes in the distribution of lung cancer cell types and patient demography in a developing multi-racial Asian country: Experience of a university teaching hospital. Lung Cancer 2006;53(1):23-30.

Hashim CW, Omar A, Abdullah S, Ismail AT. Prevalence and factors for non-resectable lung cancer at presentation. Aust Asian J Cancer 2010;9(1):61-6.

Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: Geographical distribution and secular trends. J Thorac Oncol 2008;3(8):819-31.

Srisam-Ang K, Podhipak A, Narksawat K, Supaattagorn P, Tipayamongkholgul M. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani cancer center, Thailand. Southeast Asian J Trop Med Public Health 2005;36(4):994-1006.

Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: A comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010;5(5):620-30.

Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group. Am J Med 1980;69(4):491-7.

Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: Age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002;13(7):1087-93.